Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 5mg | $55.97 | $11.19/mg | In stock | Jul 8 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| 8-3-4G121 | Apr 2026 | 99.8% | MDx BioAnalytical Laboratory | Endotoxin | Confirmed | View |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. DSIP is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does BioLongevity Labs sell DSIP?
Yes — BioLongevity Labs currently lists DSIP in 1 variant starting at $55.97 ($11.19/mg).
Is BioLongevity Labs's DSIP third-party tested?
Yes — Disclosed Labs has indexed 7 Certificates of Analysis for BioLongevity Labs's DSIP, with the most recent showing 99.8% purity. BioLongevity Labs holds an overall trust grade of C (78/100) across all 327 COAs on file.
What is BioLongevity Labs's trust grade for DSIP?
BioLongevity Labs has an overall Disclosed Labs trust grade of C (78/100), computed from 327 COAs across all peptides. The most recent DSIP COA was issued by MDx BioAnalytical Laboratory.
Where is the cheapest DSIP?
As of the latest data, Peptide Supply Co. offers DSIP at $3.00/mg — compare with BioLongevity Labs's listing at $11.19/mg. See the full DSIP price comparison.
Is DSIP legal to buy?
DSIP is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
| QC260725 | Feb 2026 | 99.8% | MDx BioAnalytical Laboratory | Endotoxin | Confirmed | View |
| 8-3-46035 | Feb 2026 | 99.8% | BioRegen | — | Confirmed | View |
| — | Jan 2026 | 99.8% | MDx BioAnalytical Laboratory | Endotoxin | Confirmed | View |
| 251535 | Oct 2025 | 99.8% | MDx BioAnalytical Laboratory | — | Confirmed | View |
| — | Apr 2025 | — | BioRegen | Endotoxin | Confirmed | View |
| — | Mar 2025 | 100.0% | BioRegen | — | Confirmed | View |
Disclosed Labs